Low risk of disease recurrence, defined by the following criteria: research hub

ATTENUATION – A multicenter randomized phase II study of the efficacy and safety de-escalation versus standard adjuvant chemotherapy in patients with low risk localized gastroesophageal adenocarcinoma (study PRODIGE/FRENCH 39)

This study looks at a new way to treat stomach and gullet cancer after surgery. Half of the patients get less chemotherapy, and the other half get the usual amount. We want to see if less treatment is just as good, safer, and helps people feel better.